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Abstract 
Objective: 
The objective of the 1st European AIDS Clinical Society (EACS) meeting on Standard of Care in 
Europe was to raise awareness about the European scenario and come to an agreement on 
actions that could be taken in the future. 
Methods: 
Data driven presentations on specific topics followed by interactive panel discussions 
Results: 
In Eastern European countries, the epidemic is largely driven by injecting drug use, in contrast 
with Western Europe where  the infection mainly occurs through heterosexual contact. A high 
proportion of people living with HIV remain unaware of their infection. Substantial differences 
exist in Eastern Europe and Central Asia with respect to treatment coverage, regimen availability 
and continuity of drug supply. In 2012, tuberculosis case notification rates were five to ten times 
higher in Eastern Europe compared to Western Europe, with an alarming proportion of newly 
diagnosed multi-drug resistant cases . Hepatitis C is widespread among selected geographic areas 
and risk groups. 
Conclusions: 
Key conclusions from the meeting were:  a high priority group of actions, such as  to increase HIV 
awareness and testing, to improve training for health care providers, to ensure equitable patient 
access to treatments and diagnostics for HIV and co-morbidities, to implement best practices in 
infection control and treatment of TB and HIV/HCV co-infected patients, should be considered for 
direct acting antivirals (DAA) treatment. 
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Introduction 
The 1st European AIDS Clinical Society (EACS) meeting on Standard of Care in Europe was held in 
Rome during the Italian semester of the EU presidency. A number of renowned lecturers were 
asked to present cutting edge data on a range of important issues including epidemiology, patient 
access to treatments, standard of care and public health. Panellists interactively discussed the 
data presented, took up important remarks from the audience and addressed key points for each 
topic. Despite the lower participation of representatives from Eastern Europe, panellists from this 
region particularly felt that this 1st Meeting should trigger further regional activities on patient 
access and standard of care 
 
Epidemiology and late presentation in the European region  
Khouloud Porter (UCL, London,UK) and Amanda Mocroft (UCL, London, UK) illustrated European 
epidemiology. 
ECDC estimates that 2.4 million people are living with HIV in the WHO European area, the 
majority (1.5 million) being in eastern Europe (including central Asia) (1), which is the only region 
in the world with rising HIV incidence (1). Since the introduction of the combination antiretroviral 
therapy (cART) in the mid-1990s, the increase in average lifespan of HIV positive subjects resulted 
in a higher prevalence of HIV infection. However, HIV prevalence has steadily increased in the 
western region (including central Europe), whilst it has steeply increased in the Eastern countries. 
At present, prevalence rates differ significantly between the two regions, being 0.8% in the East 
and 0.2% in the West (1). 
In the East, the epidemic is largely driven by injecting drug use, in contrast with the West where 
the infection mainly occurs through heterosexual contact. For instance, out  of 90,190 new cases 
diagnosed in East Europe in 2010, 43% occurred in people who inject drugs, as compared to 4% of 
28,137 new diagnoses in West Europe (2). 
In 2004, the Dublin Declaration (3) stated an ambition of halting and reversing the increasing 
trend in HIV diagnosis in the European region; although,  HIV diagnosis rates rose by 80% across 
the European region between 2004 and 2013.  Up to 76 % of all newly HIV diagnosed cases in 
2010 occurred in Eastern Europe, with 90% being in Russia and Ukraine (2). 
Approximately half of total patients are diagnosed late according to the consensus definition in 
2010 (4). Late diagnosis remains a key problem in Eastern Europe and Central Asia, and  is also a 
critical issue for migrant populations. Particularly, undocumented migrants are at disadvantage: 
they do not have access to antiretroviral therapy in 12 EU states, mainly in Central Europe (5).  
  
HIV testing 
Amanda Mocroft, (UCL, London, UK) , Deniz Gökengin, (Ege University, Izmir, Turkey), Nikos 
Dedes, (EATG, Greece), Tamás Bereczky, (EATG, Hungary) discussed on HIV testing. 
The lack of further improvements in late presentation in Europe suggests that improving the 
coverage of voluntary counselling and testing will not produce substantial effects. A number of 
settings offer opportunities to target HIV testing to those at highest risk of exposure, including 
genitourinary medicine clinics, TB clinics, drug dependence clinics and antenatal care. Indicator-
condition guided HIV testing also may help to identify undiagnosed individuals at high risk (6). 
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A high proportion of people living with HIV remain unaware of their infection, and the rates of 
undiagnosed cases range from 20% in Denmark, Sweden and Slovakia, and 30% in the United 
Kingdom, France and Germany, to as high as 50% in Poland and Latvia. Heterosexual men, older 
people, migrants and people living in areas with low HIV prevalence are more likely to remain 
undiagnosed  (1).  
Barriers to HIV testing may relate to patient, provider or structural issues. Knowing the different 
role of these barriers in the different scenarios is crucial to implement strategies for HIV testing  
(Table 1).  
Key conclusions 
A. The following key actions should be taken: 
- To increase HIV awareness and testing:  
- To increase training for healthcare providers in order to improve their attitude towards HIV 
and confidence in conducting a test.  
- To intensify research for the development of successful models for community HIV testing.  
- To make every collaborative effort to reduce stigma around HIV testing and diagnosis aiming 
for ‘normalization’ of HIV- testing as a universal testing strategy.  
- To achieve consensus that verbal informed consent is acceptable.  
- To obtain brief post-test information from those testing negative  
B. To ensure patient access to care and follow up after HIV diagnosis,  e.g. ensuring pathways to 
book appointments following test results, active follow-up of non-attenders, choice of 
providers  and periodic evaluation of retention in care 
C. Five priorities identified by ECDC to reverse the increasing trend of HIV diagnosis (7, 8). 
First: undertake appropriate targeted preventive measures for the key populations – men who 
have sex with men, people who inject drugs, migrants, prisoners and sex workers.  
Second: increase coverage and frequency of HIV testing to reduce late diagnosis. Testing should 
be community-based and governments should look for innovative methods of expanding the 
uptake of testing, as well as targeting key populations.  
Third: scale up antiretroviral treatment coverage in Eastern Europe and make antiretroviral 
therapies and care available to undocumented migrants. National programmes need to improve 
diagnosis rates and viral suppression in order to achieve the full impact of preventive  treatment.  
Fourth: promote large-scale financing, especially for civil society delivery of key prevention and 
harm reduction services. 
Fifth: exert a strong political leadership, both at national and European level, in order to mobilise 
funding and change attitudes towards HIV. 
Improving access to antiretroviral therapy 
Martina Brostrom, UNAIDS, Geneva; Cristiana Oprea, Victor Babes Hospital, Bucharest, Romania; 
Andrea Antinori, Italy; Andrzej Horban, Warsaw, Poland; Teresa Branco, Portugal.  
Combined antiretroviral therapy (cART) coverage is encouraging in many low income countries - 
even in Africa (9); however, according to UNAIDS,  treatment coverage has been estimated at 
21% in Eastern Europe and Central Asia.  
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A survey on treatment access has been carried out on behalf of EACS by Cristiana Oprea and 
Deniz Gökingen in Eastern Europe and Central Asia, and substantial differences were observed 
within regional income bands in respect of treatment coverage, regimen availability and 
continuity of drug supply.   
Lower middle-income countries  
With the exception of Ukraine, these countries have low HIV prevalence and, in most cases, are 
highly reliant on support from international funds to provide cART. HIV epidemics appear to be 
concentrated in people who inject drugs (PWID) and heterosexuals. cART coverage is lower than 
20%, and treatment is provided by infectious disease specialists. Preferred antiretroviral regimens 
are administered according to EACS or WHO guidelines, but single-dose combinations and newer 
antiretrovirals remain unavailable. Stock-outs of antiretroviral drugs have occurred in the past 
two years in most countries. 
Upper middle income countries (including Central and South-Eastern Europe) 
HIV prevalence is very low in these countries (<0.1%). Higher rates of  HIV transmission were 
reported among PWID in Azerbaijan, Kazakhstan and Romania, and MSM in Serbia, Bulgaria and 
Hungary. cART initiation is recommended at 350 CD4 cells/mm3, although Hungary and Romania 
have moved to ART initiation at 500 CD4 cells/mm3. cART coverage ranges between 30%, 45% 
and 69% in Kazakhstan,  Belarus and Romania, respectively. Preferred cART regimens reflect EACS 
guidelines. Newer agents and single-dose combinations are unavailable in most countries. Stocks-
outs have been reported in the past two years in Albania, Macedonia, Serbia and Romania. 
High-income countries (Russia & Central Europe) 
HIV prevalence is low with the exception of the Russian Federation (1%). HIV prevalence is high 
among PWID in Russia and Poland, and among MSM in Croatia, Czech Republic and Slovakia. cART 
initiation is recommended at 500 CD4 cell/mm3 - save Russia, where treatment is started at 200 
CD4 cells/mm3. cART coverage is equivalent to Western European levels (>60%) in all countries 
except Russia (20% - 34%). Preferred cART regimens are administered according to EACS 
guidelines (information unavailable for Russia). Newer agents and single dose combinations are 
available and preferred for first-line treatments in most countries. Only Russia has reported ART 
stock-outs in the past two years. 
Antiretroviral treatment in Western Europe 
In many European settings, cART prescribers face growing budgetary pressures to limit overall 
expenditure on cART and to consider the costs of individual agents. The introduction of generic 
antiretrovirals upon the expiry of patents between 2014 and 2018 is likely to force further 
consideration of prescribing costs.  
Migrants 
Forty per cent of HIV infections in the EU/EEA were diagnosed in migrants between 2007 and 
2011. A survey by ECDC found that undocumented migrants are entitled only to emergency 
medical care in 20 E/EEA countries (10). Some countries do not collect surveillance data on 
country of origin of migrants and there has been little epidemiological analysis to determine 
whether migrants have been exposed to HIV in their country of origin or in destination countries.  
Key conclusions 
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- The high cost of treatment, medicines and diagnostics for HIV and co-morbidities represents a 
significant barrier for full benefits of HIV treatment to prevent HIV-related illness, avert AIDS-
related deaths and prevent new HIV infections. 
- Governments and the EU should  develop appropriate procedures aimed at providing 
equitable and affordable access to effective medicines and diagnostics for HIV and co-
morbidities, ensuring sustainable national healthcare systems. 
- This could be done by implementing cooperative strategies to effectively manage 
pharmaceutical expenditure, including issues related to affordable pricing through  a unitary 
negotiation across Europe and the use of generic medicines. compulsory licensing, medical 
across Europe devices, and small markets. 
 
Improving retention and quality of care in particular in Eastern Europe 
Cristina Mussini, University of Modena, Italy; Jens D. Lundgren, University of Copenhagen, 
Denmark. 
Comparative analysis of care and treatment cascades in the European region shows a variety of 
weaknesses in health system performance (Table 2). 
Very high rates of viral suppression are being achieved in patients diagnosed and retained in care 
in Western Europe. Language and cultural barriers, as well as the burdens of economic recession, 
make it more likely that migrants will be lost to follow up or forced to move to seek work. 
Migrants represented 40% of HIV diagnoses in the European Union between 2007 and 2011, 92% 
of these in Western Europe. (10) 
In Eastern Europe, the lack of HIV awareness and treatment, highly restrictive eligibility criteria 
and limited availability of treatments lead to very low rates of viral suppression. Antiretroviral 
coverage remains extremely low; only 35% of people eligible for treatment were receiving ART in 
2012 -one of the lowest rate in the world.  
Improving the quality of HIV care in Eastern Europe could avert at least 80,000 deaths a year. 
Close attention should be paid to the essential elements of care. Screening and management of 
lifestyle-related comorbidities and organ dysfunction is also desirable. 
People who inject drugs need models of care which can address all their health needs at one site 
rather than to navigate multiple vertical services providing treatment for drug addiction, HIV, 
general medical care and TB.  
Opioid substitution therapy (OST) is an crucial element of care for people who inject drugs. The 
proportion of people who inject drugs receiving OST is extremely low in Eastern Europe (<5% in 
Russia, Belarus, Ukraine) compared to Western Europe (50-60% in United Kingdom, Netherlands, 
Italy). 
Key conclusions 
- Greater engagement with health care professionals in the region through invitations,  support 
to international meetings and training courses will facilitate discussions with peers on best 
practices. Moreover, in order to limit expensive traveling, a program of e-learning run by 
EACS is in preparation.  
- Political dialogue will be essential in order to ensure political leadership in Eastern Europe. 
G8-level Health Minister support, and dialogue between multilateral agencies and Health 
Ministries, will need to continue. 
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- In lower prevalence countries, EACS plays an important role in raising standards through 
training, research networks and in-country visits, and by advocating good practice also in 
arm-reduction policies through engagement with Health Ministries, who may be unaware of 
recent guidance. 
 
Coinfections 
HIV and tuberculosis 
Enrico Girardi, National Institute for Infectious Disease L Spallanzani, Rome, Italy; Daria 
Podlekareva, , Rigshospitalet, University of Copenhagen, Denmark. 
Tuberculosis (TB) case notification rates were five to ten times higher in Eastern  compared to 
Western Europe in 2012 [11] and an alarming proportion of newly diagnosed cases are multi-drug 
resistant (MDR) (32-35% in Belarus in 2010-2012; 14.4% in Russia in 2010) [12-13]. TB incidence 
among people living with HIV (PLHIV) in Russia is one of the highest in the world, with an 
incidence rate of 1,600 cases per 100,000 inhabitants.  
40% of subjects undergoing drug susceptibility testing (DST) in Eastern Europe had MDR-TB 
versus <5% in Western Europe, a low proportion of patients undergoing DST received a 
combination treatment with at least 3 active drugs, as per WHO recommendation [14-16]. 
Similarly, mortality among TB/HIV population was substantially higher in Eastern Europe than in 
the rest of Europe (33% vs 8-14% at 12 months). The increased risk of death was strongly 
associated with multi-drug resistance and disseminated disease [17, 18]. 
Regional variations in TB management and healthcare delivery, namely decentralised HIV and TB 
care, lack of anti-TB drugs, ARVs and susceptibility testing, as well as increased risk of nosocomial 
transmission during long-term hospitalisations, are likely to contribute to these poor outcomes. 
Key conclusions 
- Integration of HIV and TB services, patient-oriented health care, social support and retention 
of patients in care 
- Consistent implementation of best practice in TB and HIV infection control, and intensified 
case finding among key populations 
- Availability of rapid TB diagnostic tests and DSTs  
- Adequate adjustments of empiric TB treatment and subsequent treatments guided by DST 
results 
- Unlimited availability of all TB drugs 
- Appropriate treatment of HIV infection and unlimited cART coverage 
- Improved TB and HIV surveillance and political will  
 
Hepatitis C & HIV coinfection 
Antonella d’Arminio Monforte, University of Milan, Italy; Karine Lacombe, Hôpital St Antoine, 
Paris; Sanjay Bhagani, Royal Free Hospital, London, UK. 
HCV antibody prevalence among PLHIV is highest in Eastern Europe (57%), Central Europe (34%) 
and Southern Europe (29%) and is highly concentrated in urban populations [19]. HCV prevalence 
among injecting drug users has declined over time but an epidemic of HCV in MSM has emerged 
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in Western Europe [20-22]. The use of HCV screening in co-infected people remains variable, 
regardless of EACS guidance recommendations - particularly for MSM [23, 24]. Use of rapid tests 
for HCV and HIV antibody may improve screening rates [ 25]. 
Up to now, the proportion of co-infected patients treated for HCV infection remains very low, 
even if the risk of progression of liver disease is higher than in HIV-negative subjects, if left 
untreated (<5% per annum in the Eurosida cohort) [26, 27]. Fully suppressive antiretroviral 
therapies reduce the risk of progression in co-infected people; however, co-infected patients with 
a F4 fibrosis stage remain at high risk of decompensation [28, 29]. HIV/HCV co-infected patients 
should be considered as a high priority group for direct acting antivirals (DAA) treatment, as 
recommended in the AASLD 2014 and in EACS guidelines [30, 31]. Main barriers to hepatitis C 
treatment are listed in Table 3 [32, 33]. 
Cure rates of >90% have been reported in clinical trials conducted with co-infected patients 
treated with new interferon-free DAAs regimens [34-37].  
Cost represents the most substantial barrier to hepatitis C treatment in all European countries.  
European activists have called for an EU-wide strategic action plan to address HCV diagnosis and 
treatment, and a drug pricing for universal access to treatment. [38].  
WHO is developing a global health sector strategy on viral hepatitis and will conduct European 
consultations during the first quarter of 2015. 
Key conclusions 
Consensus discussion identified the following priority measures for action on HCV co-infection: 
- Suboptimal treatment is unacceptable 
- Support from clinical societies is needed 
- Guidelines should be updated more frequently to take into account the rapidly evolving 
knowledge on HCV treatment 
- More research is urgently needed to characterize patients at highest risk of liver 
decompensation and non-hepatic complications. 
 
 
Conclusions 
Several actions need to be implemented in order to provide better clinical care and treatment of 
HIV and co-infections across Europe. 
In particular, all reasonable efforts should be made to increase awareness on HIV testing and to 
reduce stigma around testing. Importantly, subjects diagnosed with HIV should be assured access 
to care and periodic evaluation of retention in care should be performed. Key populations, such 
as people who inject drugs, migrants, prisoners and sex workers deserve special attention for 
prevention.  
Scaling up ART across Europe, particularly Eastern Europe, is crucial and migrants should also be 
assured both care and ART availability.  The costs of ART and treating comorbidities, in particular 
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HCV and tuberculosis, should be negotiated with pharmaceutical companies both at national and 
European levels in order to guarantee access to care for every individual living in Europe. In this 
respect, the use of generic drugs could be taken into consideration once adequate combinations 
will be widely available.   
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Table 1: Barriers to HIV testing 
Barriers to HIV testing 
Patient Provider Structural 
-  
- Low risk perception 
- Lack of awareness of 
HIV and treatment 
availability 
- Fear of HIV infection 
and its health 
consequences 
- Fear of disclosure 
(worries about stigma, 
discrimination and 
rejection by significant 
others)  
- Denial 
- Difficulty in accessing 
services, especially for 
migrant populations 
 
 
 
 
o  
- Patient not perceived 
to be at risk 
- Insufficient time 
- Burdensome consent 
process 
- Lack of 
knowledge/training 
- Stereotyping – fear of 
appearing to 
discriminate 
- Pre-test counselling 
requirements 
- Reimbursement issues 
or lack of 
reimbursement 
incentives 
 
- In Eastern Europe also: 
- Corruption, including 
payments to health 
care providers for 
services 
- High prevalence of 
discriminatory 
attitudes towards key 
populations, 
sanctioned by 
authority 
 
o  
- Lack of national 
policies on HIV testing 
- Lack of services that 
are friendly to key 
populations e.g. MSM, 
drug users, Africans 
- Regulatory and 
licensing systems that 
prevent all health care 
providers from 
offering a test 
- Medical device 
regulations that 
prevent the use of 
point of care tests 
- Lack of anti-
discrimination laws 
- Criminalisation of 
people who inject 
drugs, sex workers and 
men who have sex 
with men 
 
- In Eastern Europe also: 
- Weak NGO sector 
- Lack of political 
pressure to provide 
HIV services 
- Political opposition to 
key populations at all 
levels 
- Widespread non-
adherence to 
international guidance 
and standards of good 
practice 
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Table 2. Comparative care and treatment cascades in Europe and Central Asia 
 Estimated 
HIV 
Diagnosed Linked to 
care 
Retained in 
care 
On ART Virally 
suppressed 
France 149,000 81% n/a 74% 16% 52% 
Armenia 3700 44% n/a 28% 16% 14% 
Azerbaijan 9200 47% n/a 28% 14% 10% 
Belarus 24000 50% n/a 41% 18% 13% 
Georgia 4900 52% 44% 38% 26% 20% 
Kyrgyzstan 7600 67% n/a 28% 12% ? 
Russia 1,360,000 49% 38% 35% 11.5% 9% (<1000) 
Ukraine 237,000 86% 59% ? ? 17% 
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Table 3. Barriers to hepatitis C treatment  
Patient barriers Provider barriers 
- Lack of knowledge 
- Concern regarding treatment side effects 
and treatment efficacy  claims 
- Socially and economically marginalised 
populations 
- Stigma 
- Lack of treatment guidelines 
- Lack of awareness of HIV impact on the 
progression of HCV liver disease 
- Poor collaboration between infectious 
diseases specialists and hepatologists 
- Perception that co-infected patients are at 
high risk of non-adherence and re-infection 
- Concern regarding treatment efficacy and 
tolerability claims 
- Concerns about complexity of drug-drug 
interactions 
- Cost of treatment 
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